Sanofi, Regeneron hustle Kevzara into 2nd pivotal coronavirus study

Sanofi and Regeneron's Kevzara is now being evaluated in the U.S. and abroad as a possible treatment for COVID-19. (Pixabay)

In the hunt for a COVID-19 treatment, Sanofi and Regeneron have thrown their shared IL-6 inhibitor Kevzara into the global effort. After trumpeting its plan to enroll U.S. patients in a late-stage repurposing trial, the partners have now launched a matching study outside the U.S.

Sanofi and Regeneron have dosed the first patient in the ex-U.S. arm of a global phase 2/3 clinical program evaluating Kevzara as a treatment for severe COVID-19, the partners said Monday. 

The Kevzara program will enlist severe or critically ill patients who've been hospitalized in Italy, Spain, Germany, France, Canada and Russia, and the drugmakers are working to "secure initiation at additional sites," Regeneron said in a release.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

This second trial will eventually enroll around 300 patients and study intravenous Kevzara as an add-on to supportive care through an "adaptive design," Regeneron said. 

Two weeks ago, Sanofi and Regeneron announced the U.S. arm of the program, saying the trial would test Kevzara as an add-on to supportive care in around 400 patients across 16 states. 

The first segment of the trial will study Kevzara's effects on fever and patients’ need for supplemental oxygen, while a second segment will focus on longer-term outcomes, including preventing death and cutting the need for supportive care such as mechanical ventilation, supplemental oxygen and/or hospitalization, the partners said.

RELATED: Sanofi, Regeneron ready to roll Kevzara into COVID-19 trials immediately

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.